Literature DB >> 24741084

Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Ziying Han1, Jianhong Lu1, Yuliang Liu1, Benjamin Davis2, Michael S Lee3, Mark A Olson4, Gordon Ruthel1, Bruce D Freedman1, Matthias J Schnell2, Jay E Wrobel5, Allen B Reitz5, Ronald N Harty6.   

Abstract

UNLABELLED: Budding of filoviruses, arenaviruses, and rhabdoviruses is facilitated by subversion of host proteins, such as Nedd4 E3 ubiquitin ligase, by viral PPxY late (L) budding domains expressed within the matrix proteins of these RNA viruses. As L domains are important for budding and are highly conserved in a wide array of RNA viruses, they represent potential broad-spectrum targets for the development of antiviral drugs. To identify potential competitive blockers, we used the known Nedd4 WW domain-PPxY interaction interface as the basis of an in silico screen. Using PPxY-dependent budding of Marburg (MARV) VP40 virus-like particles (VLPs) as our model system, we identified small-molecule hit 1 that inhibited Nedd4-PPxY interaction and PPxY-dependent budding. This lead candidate was subsequently improved with additional structure-activity relationship (SAR) analog testing which enhanced antibudding activity into the nanomolar range. Current lead compounds 4 and 5 exhibit on-target effects by specifically blocking the MARV VP40 PPxY-host Nedd4 interaction and subsequent PPxY-dependent egress of MARV VP40 VLPs. In addition, lead compounds 4 and 5 exhibited antibudding activity against Ebola and Lassa fever VLPs, as well as vesicular stomatitis and rabies viruses (VSV and RABV, respectively). These data provide target validation and suggest that inhibition of the PPxY-Nedd4 interaction can serve as the basis for the development of a novel class of broad-spectrum, host-oriented antivirals targeting viruses that depend on a functional PPxY L domain for efficient egress. IMPORTANCE: There is an urgent and unmet need for the development of safe and effective therapeutics against biodefense and high-priority pathogens, including filoviruses (Ebola and Marburg) and arenaviruses (e.g., Lassa and Junin) which cause severe hemorrhagic fever syndromes with high mortality rates. We along with others have established that efficient budding of filoviruses, arenaviruses, and other viruses is critically dependent on the subversion of host proteins. As disruption of virus budding would prevent virus dissemination, identification of small-molecule compounds that block these critical viral-host interactions should effectively block disease progression and transmission. Our findings provide validation for targeting these virus-host interactions as we have identified lead inhibitors with broad-spectrum antiviral activity. In addition, such inhibitors might prove useful for newly emerging RNA viruses for which no therapeutics would be available.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24741084      PMCID: PMC4054416          DOI: 10.1128/JVI.00591-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Virus budding/host interactions.

Authors:  Ronald N Harty; Anthony P Schmitt; Fadila Bouamr; Carolina B Lopez; Claude Krummenacher
Journal:  Adv Virol       Date:  2011-10-20

3.  Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.

Authors:  Dimiter G Demirov; Akira Ono; Jan M Orenstein; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 4.  Marburg and Ebola viruses.

Authors:  H Feldmann; H D Klenk
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

5.  Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin.

Authors:  Sheli R Radoshitzky; Lian Dong; Xiaoli Chi; Jeremiah C Clester; Cary Retterer; Kevin Spurgers; Jens H Kuhn; Sarah Sandwick; Gordon Ruthel; Krishna Kota; Dutch Boltz; Travis Warren; Philip J Kranzusch; Sean P J Whelan; Sina Bavari
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

6.  Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds.

Authors:  Cybele C García; Mahmoud Djavani; Ivan Topisirovic; Katherine L B Borden; María S Salvato; Elsa B Damonte
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

7.  Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras.

Authors:  R C Craven; R N Harty; J Paragas; P Palese; J W Wills
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 8.  Current drug discovery strategies against arenavirus infections.

Authors:  Antonella Pasquato; Dominique J Burri; Stefan Kunz
Journal:  Expert Rev Anti Infect Ther       Date:  2012-11       Impact factor: 5.091

9.  The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release.

Authors:  Eva Gottwein; Jochen Bodem; Barbara Müller; Ariane Schmechel; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4.

Authors:  Joanna Timmins; Guy Schoehn; Sylvie Ricard-Blum; Sandra Scianimanico; Thierry Vernet; Rob W H Ruigrok; Winfried Weissenhorn
Journal:  J Mol Biol       Date:  2003-02-14       Impact factor: 5.469

View more
  47 in total

1.  Covalent Tethering of Fragments For Covalent Probe Discovery.

Authors:  Stefan G Kathman; Alexander V Statsyuk
Journal:  Medchemcomm       Date:  2016-01-28       Impact factor: 3.597

Review 2.  Nipah virus matrix protein: expert hacker of cellular machines.

Authors:  Ruth E Watkinson; Benhur Lee
Journal:  FEBS Lett       Date:  2016-07-12       Impact factor: 4.124

3.  ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress.

Authors:  Ziying Han; Jonathan J Madara; Yuliang Liu; Wenbo Liu; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  J Infect Dis       Date:  2015-03-18       Impact factor: 5.226

4.  ITCH E3 Ubiquitin Ligase Interacts with Ebola Virus VP40 To Regulate Budding.

Authors:  Ziying Han; Cari A Sagum; Mark T Bedford; Sachdev S Sidhu; Marius Sudol; Ronald N Harty
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  The Integrity of the YxxL Motif of Ebola Virus VP24 Is Important for the Transport of Nucleocapsid-Like Structures and for the Regulation of Viral RNA Synthesis.

Authors:  Yuki Takamatsu; Larissa Kolesnikova; Martin Schauflinger; Takeshi Noda; Stephan Becker
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  A Small Molecule That Switches a Ubiquitin Ligase From a Processive to a Distributive Enzymatic Mechanism.

Authors:  Stefan G Kathman; Ingrid Span; Aaron T Smith; Ziyang Xu; Jennifer Zhan; Amy C Rosenzweig; Alexander V Statsyuk
Journal:  J Am Chem Soc       Date:  2015-09-22       Impact factor: 15.419

7.  The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.

Authors:  Jonathan J Madara; Ziying Han; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  Future Virol       Date:  2015-05       Impact factor: 1.831

Review 8.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

9.  Therapeutics for postexposure treatment of Ebola virus infection.

Authors:  Marina Jerebtsova; Sergei Nekhai
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

10.  Matrix proteins of Nipah and Hendra viruses interact with beta subunits of AP-3 complexes.

Authors:  Weina Sun; Thomas S McCrory; Wei Young Khaw; Stephanie Petzing; Terrell Myers; Anthony P Schmitt
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.